Gene Therapy Research for Parkinson's Disease

Gene therapy aims to treat Parkinson's disease at its biological roots by delivering genetic material directly into brain cells to restore dopamine production, protect surviving neurons, or correct specific genetic defects. As of early 2026, no gene therapy has been approved for Parkinson's, but multiple clinical trials are underway, including one program that has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. This article covers the science, the current state of clinical testing, and what patients should realistically expect.

How Gene Therapy Works

Gene therapy delivers a functional gene into target cells using a vector — a carrier that transports genetic material into the cell. The most commonly used vectors in Parkinson's research are adeno-associated viruses (AAVs), small, non-disease-causing viruses engineered to carry therapeutic genes without causing infection. Once inside target cells, the therapeutic gene integrates into the cell's machinery and begins producing the intended protein.

For Parkinson's, gene therapy is typically delivered directly into specific brain regions through stereotactic neurosurgery — a procedure similar to deep brain stimulation (DBS) electrode placement. The surgeon uses MRI guidance to precisely deliver the AAV vector to the target area, most commonly the putamen (involved in motor control) or the subthalamic nucleus. Unlike daily medication that must be taken indefinitely, gene therapy is designed as a one-time treatment with potentially long-lasting effects.

A comprehensive review of gene therapy trials for Parkinson's disease published in The Lancet Neurology in June 2025 assessed the entire landscape and found that while clinical improvements have been demonstrated in several trials, the field still faces significant technical and biological challenges.

Current Gene Therapy Programs

AB-1005: GDNF Gene Therapy (Most Advanced Program)

AB-1005 is an AAV2 vector that delivers the gene for human glial cell line-derived neurotrophic factor (GDNF) directly into the putamen. GDNF is a protein that supports the survival, growth, and function of dopamine neurons. The rationale is straightforward: by producing GDNF continuously within the brain, the therapy could protect surviving dopamine neurons from further degeneration — a neuroprotective strategy rather than simply replacing the lost dopamine signal.

Key milestones for AB-1005:

• FDA RMAT designation (February 2025): The FDA granted Regenerative Medicine Advanced Therapy designation, which provides additional interactions with FDA reviewers, potential priority review, and eligibility for accelerated approval. RMAT designation does not guarantee approval but signals that the FDA considers the therapy to address an unmet medical need with preliminary clinical evidence of potential benefit.
• REGENERATE-PD Phase 2 trial: An international trial across Germany, Poland, the United Kingdom, and the United States. The primary endpoint is change in normalized "good on" time over 18 months. The trial is still enrolling (estimated primary completion in 2028), and AskBio has not disclosed a topline data date.

Earlier work on GDNF delivery (via direct protein infusion rather than gene therapy) had a complicated history. Phase 2 trials of directly infused GDNF protein showed mixed results, with some patients experiencing meaningful improvement and others showing no benefit. Gene therapy aims to solve two key problems that plagued direct protein infusion: achieving adequate distribution across the target brain region and maintaining sustained GDNF levels without repeated invasive procedures.

AADC Gene Therapy (Restoring Dopamine Conversion)

AADC (aromatic L-amino acid decarboxylase) is the enzyme that converts levodopa into dopamine in the brain. As Parkinson's progresses and more dopamine neurons die, less AADC is available, making levodopa medication increasingly ineffective — the drug reaches the brain but cannot be efficiently converted to its active form.

AADC gene therapy delivers the gene for AADC directly into the putamen, enabling remaining cells to produce the enzyme and more efficiently convert levodopa to dopamine. This approach does not stop neurodegeneration, but it could significantly improve the response to existing medication.

Results from a Phase 1 trial led by researchers at the University of California, San Francisco (published in Annals of Neurology, 2019) showed that patients who received AADC gene therapy had increased AADC enzyme activity on PET scans and improvements in "on" time (when medication works effectively), with some patients able to reduce their levodopa dose. A Phase 2 trial (RESTORE-1) has been evaluating the therapy in a larger group of patients.

VGN-R09b: Dual-Mechanism Gene Therapy (AADC + GDNF)

VGN-R09b represents a novel approach that combines two therapeutic genes in a single vector: AADC (to improve levodopa conversion) and GDNF (to provide neuroprotection). The rationale is that addressing both dopamine production and neuronal survival simultaneously could provide greater benefit than either alone.

A Phase 1 registration study has completed dosing in the first group of three subjects. Results from this early-stage trial, published in 2025, are focused on safety and tolerability. If the approach proves safe, it could represent a significant advance by delivering two complementary mechanisms through a single surgical procedure.

GBA Gene Therapy (Correcting a Genetic Cause)

Mutations in the GBA1 gene are the most common genetic risk factor for Parkinson's disease, found in 10-15% of sporadic cases. The GBA1 gene encodes glucocerebrosidase (GCase), an enzyme critical for cellular waste disposal. When GCase activity is impaired, the cell's ability to clear alpha-synuclein is compromised, contributing to the toxic protein buildup that drives neurodegeneration.

Gene therapy for GBA-associated Parkinson's aims to deliver a functional copy of the GBA1 gene to brain cells, restoring normal enzyme activity and improving alpha-synuclein clearance. A first-in-human trial reported in The Lancet Neurology in 2025 used an AAV vector to deliver the corrected gene — the first trial to use gene therapy to correct a specific genetic cause of Parkinson's in humans.

This targeted approach has a clear scientific rationale for the subset of Parkinson's patients with GBA mutations, but the broader relevance depends on whether improving GCase activity benefits patients with normal GBA genes — an open question being investigated through pharmacological GCase activators. One such candidate, BIA 28-6156, failed its Phase 2b ACTIVATE trial in GBA-related Parkinson's and was discontinued in June 2026; another, GT-02287, remains in Phase 1b testing.

GAD Gene Therapy (Circuit Modulation)

Glutamic acid decarboxylase (GAD) gene therapy takes a different approach: rather than targeting dopamine, it delivers the gene for the enzyme that produces GABA (the brain's primary inhibitory neurotransmitter) to the subthalamic nucleus, which becomes overactive in Parkinson's. The goal is to reduce this overactivity — essentially achieving a similar effect to DBS but without implanted hardware.

A Phase 2 trial showed statistically significant improvements in motor scores compared to sham surgery, though the improvements were modest. Further development has been slow, but the approach remains important as a proof of concept that gene therapy can modulate brain circuits in Parkinson's disease.

Challenges and Limitations

Gene therapy for Parkinson's faces several significant challenges that require honest assessment:

• Brain surgery is required. Current gene therapies require stereotactic neurosurgery, which carries inherent risks including bleeding, infection, and anesthesia complications. Research into less invasive delivery methods — such as AAV vectors engineered to cross the blood-brain barrier after intravenous injection — is active but years from clinical application.
• Adequate brain coverage is technically difficult. Ensuring that the therapeutic gene reaches enough cells in the target region is challenging. Inadequate coverage may explain why some earlier trials (notably the neurturin/CERE-120 trials) did not show the expected clinical benefit despite confirmed gene expression in the brain.
• Duration of effect is uncertain. While the delivered gene is expected to produce the therapeutic protein for years, the ongoing neurodegeneration of Parkinson's may eventually overwhelm the benefit as the cells harboring the gene die. Long-term follow-up data are still limited.
• Pre-existing immunity to AAV vectors. Some people have antibodies to AAV from natural exposure to similar viruses, which could reduce the therapy's effectiveness. Screening for these antibodies is part of trial eligibility, but it also means a subset of patients may not be candidates.
• Irreversibility. Unlike medication that can be adjusted or stopped, gene therapy is essentially permanent. This raises the stakes for both efficacy and safety and means the bar for approval is appropriately high.
• Cost. Gene therapies approved for other conditions have been priced at $1 million to $3.5 million per treatment. If Parkinson's gene therapies are approved, access and affordability will be significant concerns, particularly given the large number of people living with the disease.

What Gene Therapy Is — and What It Is Not

Setting accurate expectations is essential:

• Gene therapy is not a cure. None of the current approaches can stop or reverse the underlying neurodegenerative process entirely. They aim to improve symptoms (AADC), protect remaining neurons (GDNF), or correct specific genetic defects (GBA).
• Gene therapy is not gene editing. Current Parkinson's gene therapies add new genetic material — they do not alter the patient's own DNA. Gene editing technologies such as CRISPR are being explored in preclinical Parkinson's research but are further from clinical testing.
• Gene therapy is not available outside clinical trials. All current Parkinson's gene therapies are experimental. Any clinic offering gene therapy for Parkinson's outside of a registered clinical trial should be treated with extreme caution.

Realistic Timeline Assessment

Based on the current state of clinical development, the following timelines are reasonable estimates — not guarantees:

• AB-1005 GDNF gene therapy: Phase 2 still enrolling, with estimated primary completion in 2028. If positive, a Phase 3 trial would follow, with a potential FDA approval timeline of 2029-2031 at the earliest.
• AADC gene therapy: Phase 2 data from RESTORE-1 will inform next steps. A regulatory path to approval, if efficacy is confirmed, could follow a similar timeline.
• GBA gene therapy: Currently in first-in-human testing. Phase 2-3 trials, if initiated, would likely not produce approvable data before 2030 at the earliest.
• VGN-R09b (dual AADC+GDNF): In Phase 1 with initial dosing complete. The earliest possible approval is likely beyond 2030.

These timelines reflect the standard pace of drug development, which historically takes 10-15 years from initial clinical testing to approval. The RMAT designation for AB-1005 could accelerate the regulatory process somewhat, but the fundamental requirement for adequate safety and efficacy data remains.

How to Get Involved

If you are interested in gene therapy research, the first step is to discuss your eligibility with your neurologist or movement disorder specialist. Gene therapy trials have specific eligibility criteria, often including age range, disease duration, levodopa responsiveness, and the absence of certain medical conditions.

You can search for open gene therapy trials at ClinicalTrials.gov (search "Parkinson's gene therapy") or through the Michael J. Fox Foundation's Fox Trial Finder. For personalized guidance, contact the Parkinson's Foundation Helpline at 1-800-4PD-INFO (1-800-473-4636).